Thursday - July 30, 2026
Oral semaglutide lowers risk of heart failure events in people with Type 2 diabetes
February 26, 2026
PORTLAND, Oregon, Feb. 26 -- Oregon Health and Science University issued the following news:

* * *

Oral semaglutide lowers risk of heart failure events in people with Type 2 diabetes

*

An international clinical trial has found that an oral form of semaglutide, a widely used diabetes drug, reduced the risk of serious heart failure events in people with Type 2 diabetes who already had heart failure.

The findings, published in JAMA I . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products